Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: GlobeNewswire
ANB032 was well tolerated across all doses with no safety signals observedAD trial and all further investment in ANB032 will be discontinuedAnticipate top-line Phase 2b data in rheumatoid arthritis in February 2025 for rosnilimab, a PD-1+ T cell depleter and agonistFunded beyond additional clinical data catalysts including Phase 2 data in ulcerative colitis for rosnilimab and Phase 1b data for ANB033 and ANB101Year-end 2024 cash of approximately $415 million and extending cash runway guidance through year-end 2027, excluding potential GSK milestones and royalties SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczem
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- GSK's combo therapy trial for advanced ovarian cancer meets primary endpoint [Yahoo! Finance]Yahoo! Finance
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $66.00 to $36.00. They now have an "overweight" rating on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Truist Financial Co. from $30.00 to $20.00. They now have a "hold" rating on the stock.MarketBeat
- AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at Wells Fargo & Company from $56.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- AnaptysBio Stock Down as Eczema Study Fails to Meet Goals [Yahoo! Finance]Yahoo! Finance
ANAB
Earnings
- 11/5/24 - Beat
ANAB
Sec Filings
- 1/2/25 - Form 4
- 12/18/24 - Form SCHEDULE
- 12/11/24 - Form 8-K
- ANAB's page on the SEC website